Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT04886531

Recruiting now Disease control Sponsor: Ruth O'Regan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast cancer. Thirty participants will receive the drugs for up to 24 weeks before surgery, and doctors will check if no cancer remains in the removed breast tissue. The goal is to improve the chances of a complete response before standard post-surgery treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
neratinib, letrozole or anastrozole, and trastuzumab
What this could lead to
If successful, this combination could increase the chance of eliminating all signs of breast cancer before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer HER2 positive breast carcinoma progesterone-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ER POSITIVE BREAST CANCER HER2-POSITIVE BREAST CANCER PR-POSITIVE BREAST CANCER

Contacts and locations

Locations

  • Penn State Cancer Institute

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • University of Illinois Cancer Center

    RECRUITING

    Chicago, Illinois, 60612, United States

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.